

TB Saracen Global Income and Growth Fund

July 2019

SARACEN
share success




Fund Overview

- Objective: to provide a degree of income to investors with the aim of building capital through investing in a portfolio of primarily global equities.
- Focus: on identifying leading global businesses with lower risk and share valuations that underestimate their prospects.
- Research: we conduct intensive proprietary research focusing on businesses' long-term earnings potential.
- Risk: we model a 'worst-case' scenario into our share valuation methodology and abide by strict sector limits.
- Process: Disciplined, structured and repeatable.
- Conviction Portfolio: high active share and highly differentiated.
- Both fund managers have significant personal investments in the fund.

Performance Chart*

Performance since launch (%)



*Source: Financial Express, as at 31st July 2019.

Total Return, Bid to Bid, GBP terms. Past performance is not a reliable indicator of future results. The value of your investment and the income derived from it can go down as well as up and you may not get back the money you invested.

Cumulative Performance after all ongoing charges to 31 July 2019

	1 month	6 months	1 year	3 years	5 years	Since launch*
TB SGIG B Acc	+2.4%	+11.5%	+2.1%	+30.7%	+56.3%	+118.0%
Sector Average	+3.9%	+14.3%	+8.7%	+32.1%	+59.4%	+110.5%
Quartile Ranking	4	3	4	3	3	2

Source: Financial Express; *launch date 07 June 2011

Sector: IA Sector (Global Equity Income)

FOR PROFESSIONAL INVESTORS ONLY

Retail investors should consult their financial advisers

FUND DETAILS

(as at 31st July 2019)

Fund size: £125m
Launch date: 07/06/11
Historic yield: 3.6%

No. of holdings: 40
Active share: 93%
Beta: 0.94

Source: Bloomberg as at 31/07/19

Turnover: <20%
Denomination: GBP
Valuation point: 12:00 noon

XD date: 2 Jan
 1 July

Pay date: 28/29 Feb
 31 Aug

Fund prices:
B Accumulation: 217.49p
B Distribution: 169.23p

Policy is not to charge a dilution levy except in exceptional circumstances.

ACD:
T. Bailey Fund Services Limited

Graham Campbell
 Chief Executive Officer

David Keir
 Executive Director



Graham Campbell joined Saracen in 2011 from Edinburgh Partners, where he was one of the founding partners and director. He has managed the Fund since launch. Graham has over 30 years of industry experience.

David Keir joined Saracen in 2013 and has managed the Fund since 2014. He has over 18 years of industry experience.




TB Saracen Global Income and Growth Fund

July 2019

SARACEN
share success



Fund Breakdown by Geography



Data as of 31st July 2019, Source: Bloomberg/Saracen Fund Managers

Monthly Commentary

Performance

This month, the total return for TB SGIG was +2.4%, compared to +3.9% for the IA Global Equity Income sector. The fund's current "value" bias continues to hold back performance. The fund remains attractively valued trading on 11.3X Year 1 PER and yielding 4.4%. TB SGIG has delivered a return of 118% since launch.

FX

Currency movements had a significant positive impact on the fund's performance. Sterling was down 2.6%, 2.1% and 4.2% against the CHF, EUR and USD respectively.

Positives

July marked the beginning of our companies reporting their Q2 results. Whilst overall results have been relatively robust, economic growth is slowing and companies are generally more cautious about the outlook. Our recent blog on the Tobacco sector highlighted a valuation opportunity. It was pleasing to see Philip Morris's (+16%) strong results on the back of the successful continued global roll-out of their Heat Not Burn product and an upgrade to their full year guidance. Imperial Brands (+13%) continued its recovery after, at long last, removing their 10% dividend growth policy. They will now grow the dividend in-line with earnings and initiate a Share Buy Back. Intel (+14%) reported better than expected results and marginally upgraded their full year guidance. IBM (+13%) closed their acquisition of Red Hat and announced solid Q2 results. AstraZeneca (+10%) raised its revenue guidance on the back of the success of its new cancer drugs.

Negatives

Allied Irish Bank (-12%) reported disappointing numbers with a weaker net interest margin and higher costs than expected. It was also impacted by the ramp up in "no-deal Brexit" rhetoric. Pfizer (-7%) shares fell despite reporting solid numbers and spinning off their off-patent drugs into a new company with Mylan. Michelin (-8%) shares fell after lowering its expectations for the global tyre market. Management still held their guidance for the year as they expect to take a higher market share.

Portfolio Activity

There were no new stocks bought or sold during the month. During July we continued to build positions in Barclays and Sabre. We also topped up our holdings in BMW, Dow Inc, Imperial Brands and InterPublic Group. We funded this by taking profits in AstraZeneca, Chevron, Cisco, Evonik, Heidelberg Cement, Rio Tinto and Schneider.

July – Attribution *

Top Contributors	Positive
Philip Morris Intl	+0.60%
IBM	+0.52%
Imperial Brands	+0.43%
Intel	+0.34%
InterPublic Group	+0.28%
Top Detractors	Negative
Allied Irish Bank	-0.29%
ProSieben	-0.21%
Pfizer	-0.16%
Michelin	-0.15%
Heidelberg Cement	-0.15%

*Source: Bloomberg as at 31/07/19

Fund Breakdown

Top 10 Holdings	
Roche	4.5%
Saint Gobain	4.1%
IBM	4.1%
Philip Morris Intl	3.9%
Heidelberg Cement	3.6%
HSBC	3.6%
Johnson Matthey	3.5%
Imperial Brands	3.4%
InterPublic Group	3.3%
DBS Group	3.3%

Sector breakdown	
Financials	18.3%
Industrials	16.8%
Healthcare	16.6%
Technology	11.6%
Basic Materials	11.1%
Consumer Goods	9.3%
Consumer Services	8.7%
Oil & Gas	7.2%
Utilities	0.0%
Cash	0.3%

	ISIN	SEDOL	Bloomberg	EMX	Initial Charge	Annual Charge	Ongoing ** Charge
B Acc Shares	GB00B5B35X02	B5B35X0	SARBACC LN	SARGGIFA	0%	0.75%	0.99%
B Dis Shares	GB00B3XPLG55	B3XPLG5	SARGIGA LN	SARGGIFD	0%	0.75%	0.99%

** Source: T Bailey Fund Services Ltd

To place a deal or for further information contact:

T. Bailey Fund Services Limited (TBFS)
64 St. James's Street
Nottingham
NG1 6FJ

General Enquiries: 0115 988 8200
Dealing Line: 0115 988 8274
E-mail Dealing: clientservices@tbailey.co.uk

(Phone and email deals will only be accepted on completion of initial account set up and by prior agreement with TBFS)

T. Bailey Fund Services Limited is authorised and regulated by the Financial Conduct Authority (No. 190293).

Platform Partners



Important information:

This information should not be construed as an invitation, offer or recommendation to buy or sell investments, shares or securities or to form the basis of a contract to be relied on in any way and is by way of information only. Taxation levels, benefits and reliefs may all vary depending on individual circumstances and are subject to change. The historic yield reflects distribution payments declared by the fund over the previous year as a percentage of its share price. This document represents the views of Saracen Fund Managers Limited at the time of writing. Subscriptions will only be received and shares issued on the basis of the current Prospectus, Key Investor Information Document (KIID) and Supplementary Information Document (SID). These are available, in English, together with information on how to buy and sell shares, on-line at: www.tbaileyfs.co.uk.

Risk factors you should consider before investing:

The value of investments and the income from them may go down as well as up and you may get back less than the amount invested. **Past performance is not a guide to future performance.** A full list of the risks applicable to this Fund can be found in the Prospectus. All fund performance figures calculated on a single price basis. This Fund may not be appropriate for investors who plan to withdraw their money in the short-term (within 5 years). The Fund should be viewed as a medium to long-term investment only.

Investment Manager:

Saracen Fund Managers Ltd, 19 Rutland Square, Edinburgh, EH1 2BB. Tel: 0131 202 9100 and on-line at www.saracenfundmanagers.com. Saracen Fund Managers Limited is authorised and regulated by the Financial Conduct Authority. Registered in Scotland No. 180545.

Issued by Saracen Fund Managers Limited. Please note that Saracen Fund Managers Limited do not provide financial advice. If you have any doubt whether the TB Saracen Global Income and Growth Fund is suitable for you and you wish to receive advice you should contact your Financial Adviser.

Regulatory Status:

FCA Recognised: Yes
Scheme Type: OEIC (UCITS)

Issue date – 31st July 2019